Venous thromboembolism risk in patients with locoregional urothelial tract tumors

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Ramos, Jorge D.ca
• dc.contributor.author Wingate, Jonathan T.ca
• dc.contributor.author Gulati, Romanca
• dc.contributor.author Plimack, Elizabeth R.ca
• dc.contributor.author Harshman, Lauren C.ca
• dc.contributor.author Powles, Thomasca
• dc.contributor.author Crabb, Simon J.ca
• dc.contributor.author Niegisch, Günterca
• dc.contributor.author Bellmunt Molins, Joaquim, 1959-ca
• dc.contributor.author Ladoire, Sylvainca
• dc.contributor.author De Giorgi, Ugoca
• dc.contributor.author Hussain, Syedca
• dc.contributor.author Alva, Ajjai S.ca
• dc.contributor.author Baniel, Jackca
• dc.contributor.author Agarwal, Neerajca
• dc.contributor.author Rosenberg, Jonathan E.ca
• dc.contributor.author Vaishampayan, Ulka N.ca
• dc.contributor.author Galsky, Matthew D.ca
• dc.contributor.author Yu, Evan Y.ca
• dc.date.accessioned 2018-05-07T08:07:11Z
• dc.date.issued 2018
• dc.description Data de publicació electrónica: 24-08-2017
• dc.description.abstract BACKGROUND: Venous thromboembolism (VTE) is common in cancer patients, but there is limited data on patients with urothelial tract tumors (UTT). We previously identified several associative factors for increased VTE rates in patients with metastatic UTT. In this study, we assessed the frequency, associative factors, and impact on survival of VTE in patients with locoregional UTT. METHODS: Patients with locoregional bladder, upper urinary tract, or urethral cancer were included in this multi-center study from 29 academic institutions. Patients with < cT2, > N1, or M1 disease at diagnosis were excluded. Patients with incomplete clinical staging or miscoded/missing data were excluded. Cumulative, unadjusted VTE incidence was calculated from time of diagnosis of muscle-invasive disease, excluding VTEs diagnosed in the metastatic setting. χ2 statistics tested differences in VTE rates across baseline and treatment-related factors. Significant covariates were incorporated into a multivariate, logistic regression model. Overall survival stratified by VTE was estimated using Kaplan-Meier methods and evaluated using the log-rank test. RESULTS: A total of 1732 patients were eligible. There were 132 (7.6%) VTEs. On multivariate analysis, non-urothelial histology (P < .001), clinical Nx stage (P < .001), cardiovascular disease (P = .01), and renal dysfunction (P = .04) were statistically significant baseline factors associated with VTE. Using surgery alone as reference, surgery with perioperative chemotherapy (P = .04) and radiation with concurrent chemotherapy (P = .04) also were significant. CONCLUSIONS: The VTE incidence of 7.6% in locoregional disease is comparable with our previously reported rate in the metastatic setting (8.2%). Similar to our findings in metastatic UTT, non-urothelial histology, renal dysfunction, and CVD was associated with increased VTE risk.
• dc.format.mimetype application/pdf
• dc.identifier.citation Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T. et al. Venous thromboembolism risk in patients with locoregional urothelial tract tumors. Clin Genitourin Cancer. 2018 Feb; 16(1):e161-7. DOI: 10.1016/j.clgc.2017.08.001
• dc.identifier.doi http://dx.doi.org/10.1016/j.clgc.2017.08.001
• dc.identifier.issn 1558-7673
• dc.identifier.uri http://hdl.handle.net/10230/34575
• dc.language.iso eng
• dc.publisher Elsevierca
• dc.relation.ispartof Clinical Genitourinary Cancer. 2018 Feb;16(1):e161-7
• dc.rights © Elsevier http://dx.doi.org/10.1016/j.clgc.2017.08.001
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword Bladder cancer
• dc.subject.keyword Localized
• dc.subject.keyword Metastatic
• dc.subject.keyword Non-urothelial
• dc.subject.keyword Thrombosis
• dc.subject.other Bufeta -- Càncer
• dc.subject.other Trombosi
• dc.title Venous thromboembolism risk in patients with locoregional urothelial tract tumorsca
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion